Loading... Please wait... Loading... Please wait...
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
Throughout much of the new normal, the concept of short-squeeze stocks took off like wildfire. Essentially, this tactic centers on taking a contrarian bet against bearish traders in Wall Street's vers...
NEW YORK , Sept. 26, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breache...
NEW ORLEANS, Sept. 21, 2022 /PRNewswire/ — Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merge...
NEW YORK , Aug. 11, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches...
Gemini Therapeutics, Inc. (GMTX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revision...
H.C. Wainwright initiated coverage of Gemini Therapeutics Inc (NASDAQ: GMTX) with a Buy rating and $20 price target. In the near term, the expected Phase 2a readout for lead asset GEM103 can ser...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular de...
Gemini Therapeutics (GMTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season....
The stock price of Gemini Therapeutics Inc (NASDAQ: GMTX) fell over 10% this week. This is why it happened....
